

UW Health Emergency Department (UH & TAC) Oritavancin Use Flowchart

Contact for Content: Lucas Schulz, PharmD; 608-890-8617; LSchulz2@uwhealth.org

Abbreviations:
 ABX: Antibiotic
 ABSSSI: Acute Bacterial Skin and Skin Structure Infections
 MPP: Multipurpose Procedure Room
 CDU: Clinical Decision Unit
 UH: University Hospital
 TAC: The American Center




Table 1. Oritavancin Exclusion Criteria

1. Sepsis or Septic shock
2. ABSSSI including:
 - Orbital cellulitis
 - Diabetic foot infections
 - Burn related infection
 - Bite wound
 - Osteomyelitis
 - Necrotizing fasciitis
 - Catheter/device related infection
 - Environmental/polymicrobial source
3. Severe allergy to:
 - Oritavancin
 - Dalbavancin
 - Vancomycin
 - Daptomycin
 - Telavancin
4. CDU or inpatient admission planned
5. Age < 18 years old

Table 2. Risk Factors for Oral Antibiotic Outpatient Treatment Failure

1. Psychosocial concern for adherence
2. Acquired Immunodeficiency Syndrome
3. Intravenous Drug User
4. Cognitively impaired
5. Chronic edema
6. Lymphedema
7. Chronic leg ulcers
8. Cirrhosis
9. Duration of infection greater than 7 days
10. History of ABSSSI at same site within last 3 months
11. Oral treatment failure (>24 hours of appropriate therapy)*
12. Incarcerated
13. Diabetes mellitus
14. Immunosuppression

*Expanding redness does not necessarily mean treatment failure